Skip to content
drillr.ai
Sign up

02652.HK

CF PharmTech, Inc.

HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN

HKD 5.30
−5.86%
Ask drillr

  • Oct 6, 2026, 01:50 UTC

    Changfeng Pharmaceutical's co-founders and core management, Liang Wenqing and Li Li, voluntarily extended the lock-up period on their shares by six months, from October 8, 2026 to April 7, 2027.

    Source:

  • Sep 22, 2026, 01:40 UTC

    Changfeng Pharmaceutical announced that its inhaled powder ICF004 for interstitial lung disease completed enrollment and dosing of the first healthy volunteer in its Phase 1 clinical trial.

    Source:

  • Aug 31, 2026, 18:00 UTC

    Changfeng Pharmaceutical reported interim results for the six months ended June 2026, with revenue of RMB 210 million, up 2.1% year-on-year, gross profit of RMB 161 million, up 3.2%, and a net loss widening to RMB 10.51 million from RMB 1.23 million in the prior-year period, with no dividend declared.

    Source: